An Act To Improve Access to Treatments for Lyme Disease
Sec. 1. 32 MRSA §3282-B is enacted to read:
§ 3282-B. Lyme disease treatment
(1) The presence of signs or symptoms compatible with acute infection with Borrelia burgdorferi;
(2) Late stage, persistent or chronic infection with Borrelia burgdorferi;
(3) Complications related to an infection under subparagraph (1) or (2); or
(4) The presence of signs or symptoms compatible with acute infection or late stage, persistent or chronic infection with other strains of Borrelia that are identified or recognized by the United States Department of Health and Human Services, Centers for Disease Control and Prevention as a cause of disease.
"Lyme disease" includes an infection that meets the surveillance criteria for Lyme disease established by the federal Centers for Disease Control and Prevention or a clinical diagnosis of Lyme disease that does not meet the surveillance criteria for Lyme disease set by the federal Centers for Disease Control and Prevention but presents other acute and chronic signs or symptoms of Lyme disease as determined by a patient's treating physician.